Mitochondria-Damaging Self-Reporting Probe for Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Chemotherapy often damages mitochondria, disrupting mitochondrial membrane potential (ΔΨm), a key factor in drug efficacy.
• Current methods using fluorescent probes to assess ΔΨm-targeting drugs are unreliable, leading to inaccurate conclusions and hindering drug development.

Purpose of the Study:

• To develop a novel class of self-reporting chemotherapeutic agents (DPPs) for direct, non-invasive monitoring of mitochondrial drug action.
• To evaluate the efficacy and safety of DPPs in preclinical cancer models.

Main Methods:

• Synthesized and characterized a series of cationic chemotherapeutic small molecules (DPPs) with intrinsic fluorescence.
• Assessed the ability of DPPs to disrupt mitochondrial function, induce reactive oxygen species (ROS), and trigger apoptosis.
• Investigated the mitochondrial-to-nuclear translocation of DPPs in real-time.
• Evaluated tumor growth inhibition and systemic toxicity in vivo.

Main Results:

• DPPs exhibit intrinsic fluorescence, enabling self-reporting of their action without external probes.
• DPP-1 and DPP-2 disrupt mitochondrial function, increase ROS generation, and induce selective apoptosis.
• Concentration-dependent mitochondrial-to-nuclear translocation of DPPs allows real-time visualization of therapeutic progression.
• In vivo studies demonstrated potent tumor growth inhibition with negligible systemic toxicity.

Conclusions:

• DPPs offer a reliable platform for monitoring mitochondria-targeted chemotherapy, overcoming limitations of current fluorescent probes.
• The self-reporting capability of DPPs facilitates real-time assessment of drug efficacy at the subcellular level.
• This mitochondria-targeted chemotherapeutic strategy holds promise for integrated cancer diagnosis and precision therapy.